-
Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA Blood Test Since Its Launch A Year Ago -
Scipher Medicine Appoints Dr. Michael Elliott to its Science Advisory Board -
Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility - America’s Choice Provider Network Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care
-
Scipher Medicine® Appoints Sam Asgarian, M.D., MBA, Chief Medical Officer -
RxParadigm Partners with Scipher Medicine® to Support Medication Utilization, Improve Patient Outcomes, and Lower Costs for Rheumatoid Arthritis Care -
Scipher Medicine® to Present at the Jeffries London Healthcare Conference -
A molecular signature response classifier to predict inadequate response to tumor necrosis factor-α Inhibitors: the NETWORK-004 Prospective Observational Study - Scipher Medicine® to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
-
Discontinuation of TNFi treatment among Rheumatoid Arthritis patients with a molecular signature of non-response to tumor necrosis factor-ɑ inhibitor therapies -
A molecular signature response classifier predicts the likelihood of non-response to TNF inhibitor therapies in RA at 3 months -
GNS Healthcare and Scipher Medicine® Collaborate to Develop World’s First in silico Patient for Rheumatoid Arthritis -
TARA Biosystems Partners with Scipher Medicine® -
Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis -
Trellis Rx Furthers Commitment to Advancing the Specialty Pharmacy Practice and Patient Outcomes with Integration of Scipher Medicine® PrismRA® Precision-Medicine Technology into Clinical Pathways